Endocrinology Advisor19h
Zepbound Approved for Obstructive Sleep Apnea in Patients With Obesity
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
24/7 Wall St3d
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...
MedCity News3d
FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
WISH-TV4d
Lilly’s Zepbound approved by FDA for sleep apnea treatment
The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...
Quick, simple nasal swab helps diagnose type of asthma in children
A new quick-and-easy nasal swab test for kids can diagnose the specific immune system drivers behind their asthma, ...
verywellhealth4d
Zepbound Gets FDA Approval to Treat Sleep Apnea
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
Study suggests estrogen may trigger binge drinking
The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...